Articles related to INSOMNIA/SLEEP DISORDERS

In 2021, melatonin was the most frequently reported substance involved in pediatric substance ingestions, resulting in 4,000 hospitalizations, 287 ICU admissions, and 2 deaths in children under the age of 2. Melatonin supplements can have 500% more melatonin than indicated on the label and about 30% of OTC products tested had serotonin as well.

The findings were presented at the 2022 Annual Meeting of the American Academy of Sleep Medicine and the Sleep Research Society. The researchers gathered the data from eight different studies that explored the safety profile of ashwagandha — an herb also known as Indian Ginseng, winter cherry, or poison gooseberry — as well as the clinical significance of its beneficial effects.

Scientists have made a breakthrough when it comes to triggering lucid dreams. Building on their previous work, researchers at the University of Wisconsin–Madison and the Lucidity Institute in Hawaii wanted to investigate how acetylcholinesterase inhibitors might promote lucid dreaming. A common drug used to treat memory decline in Alzheimer’s disease – galantamine – is a fast-acting AChEI with only mild side effects, so researchers recruited 121 participants to see what effect the drug had on their ability to have and recall lucid dreams. The findings were surprising.

The American Academy of Sleep Medicine (AASM) is taking issue with the US Senate’s recently passed legislation that will make daylight saving time (DST) permanent starting in 2023. AASM cautions that this permanent change would lead to health risks that include adverse cardiovascular events, mood disorders, and motor vehicle crashes. The group advocates for establishing permanent standard time instead.

A proposed six-step approach to making sense of arterial blood gas (ABG) labs. This six-step process with simple table support helps ensure a complete and understandable interpretation of every ABG.

Orexin receptor antagonists work by suppressing the wake drive through blocking wake-promoting neuropeptides. Daridorexant is the third dual-orexin inhibitor to receive FDA approval for people with difficulty in sleep onset or sleep maintenance.